Howard Gurney

1992–2025 年に発表

120
論文数
33,390
被引用数
60
h 指数
111
i10 指数

被引用数

Howard Gurney の年別被引用数1993 年: 被引用 4 件1994 年: 被引用 4 件1995 年: 被引用 6 件1996 年: 被引用 5 件1997 年: 被引用 10 件1998 年: 被引用 13 件1999 年: 被引用 5 件2000 年: 被引用 13 件2001 年: 被引用 27 件2002 年: 被引用 22 件2003 年: 被引用 15 件2004 年: 被引用 16 件2005 年: 被引用 13 件2006 年: 被引用 14 件2007 年: 被引用 18 件2008 年: 被引用 32 件2009 年: 被引用 18 件2010 年: 被引用 23 件2011 年: 被引用 16 件2012 年: 被引用 25 件2013 年: 被引用 15 件2014 年: 被引用 29 件2015 年: 被引用 30 件2016 年: 被引用 182 件2017 年: 被引用 264 件2018 年: 被引用 357 件2019 年: 被引用 1,326 件2020 年: 被引用 1,880 件2021 年: 被引用 1,903 件2022 年: 被引用 1,561 件2023 年: 被引用 1,200 件2024 年: 被引用 2,036 件2025 年: 被引用 922 件2026 年: 被引用 16 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,162 件、この内訳の 22.1%中国: 引用元論文 1,473 件、この内訳の 10.3%イタリア: 引用元論文 890 件、この内訳の 6.2%イギリス: 引用元論文 854 件、この内訳の 6%フランス: 引用元論文 826 件、この内訳の 5.8%日本: 引用元論文 757 件、この内訳の 5.3%ドイツ: 引用元論文 630 件、この内訳の 4.4%スペイン: 引用元論文 593 件、この内訳の 4.1%カナダ: 引用元論文 543 件、この内訳の 3.8%オーストラリア: 引用元論文 455 件、この内訳の 3.2%オランダ: 引用元論文 408 件、この内訳の 2.8%スイス: 引用元論文 288 件、この内訳の 2%
0%22.1%その他 24%

分野

  • Medicine81.6%
  • Biochemistry, Genetics and Molecular Biology11.3%
  • Immunology and Microbiology4.4%
  • Engineering0.6%
  • Mathematics0.4%
  • Pharmacology, Toxicology and Pharmaceutics0.4%
  • その他1.3%

トピック

  • Cancer Immunotherapy and Biomarkers17.5%
  • Renal cell carcinoma treatment7.4%
  • Bladder and Urothelial Cancer Treatments5.5%
  • Immunotherapy and Immune Responses3.8%
  • Ferroptosis and cancer prognosis3.8%
  • CAR-T cell therapy research3.1%
  • その他58.9%

共著者

全論文

検索で開く
  1. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hans J. Hammers, Bernard Escudier - New England Journal of Medicine 2018 被引用: 4,643

  2. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 被引用: 5,890

  3. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri - New England Journal of Medicine 2021 被引用: 1,761

  4. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 被引用: 2,550

  5. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 被引用: 3,390

  6. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2020 被引用: 1,479

  7. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jaqueline Willemann-Rogerio, David I. Quinn, Thomas Powles - New England Journal of Medicine 2021 被引用: 746

  8. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Howard Gurney, Elizabeth Hovey, Anthony M. Joshua, Matos Marco, Gavin Marx, Michelle Morris, Siobhan Ng, David Pook, Shahneen Sandhu, Ali Tafreshi, Thean Hsiang Tan, Tsvetanka Tosheva, Livia Andrade, Felipe Melo Cruz, Luiza Dib Batista Bugiato Faria, J. M. L. Figueiredo, Fábio Franke, Andrea Juliana Gomes, Ariel Galapo Kann, Celio Kussumoto, Suelen Patrícia dos Santos Martins, André M. Murad, Hélio Pinczowski, Giovani Thomaz Pioner, Luís Ferreira Pires, Daniel D’Almeida Preto, Gisele Marinho dos Santos, Eduardo Silva, Jamile Silva, Luciano de Souza Viana, Karina Vianna, Adriano Augusto Peclat de Paula, Zhiwen Chen, Kim Chi, Urban Emmenegger, Neil Fleshner, Sunil Parimi, Fred Saad, Francisco Vera-Badillo, Hongqian Guo, Hong Luo, Lulin Ma, Mingxing Qui, Wei Xue, Guo Yonglian, Lei Li, Jinxian Pu, Song Zheng, Qing Zou, Miloš Broďák, Milan Hora, Vladimír Šámal, Vladimír Študent, J Vaňásek, Emmanuelle Bompas, Philippe Barthélémy, Delphine Borchiellini, Aude Fléchon, Hakim Mahammedi, Guilhem Roubaud, Antoine Thiery-Vuillemin, Diégo Tosi, Dominique Spaëth, Carole Hélissey, Martin Boegemann, Susan Feyerabend, Eva Hellmis, Martin Schostak, Gerhardt Attard, Anna Lydon ほか 141 名 - Journal of Clinical Oncology 2023 被引用: 319

  9. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marjorie C. Green, Robert J. Motzer - The Lancet 2019 被引用: 1,010

  10. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michiel S. van der Heijden, Andrea Necchi, Daniel Castellano, Aristotelis Bamias, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Bernhard J. Eigl, Marinos Tsiatas, Thomas Powles, Andrey Novikov, Iwona Skoneczna, Som D. Mukherjee, Cristina Suárez, Hans M. Westgeest, Yves Fradet, Aude Fléchon, Yen‐Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez‐Valderrama, Susanna Cheng, Stephen Jay Frank, Howard Gurney, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala S. Sridhar, Giorgio V. Scagliotti, Jens Voortman, B. Yа. Alekseev, Anna Alyasova, B. K. Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, José Ángel Arranz, Djura Piersma, Sang Joon Shin, O. B. Karyakin, Ignacio Delgado, José Luis González, See‐Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas W. Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, M. Doménech, Yen‐Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, V. Georgoulias, Sasja F. Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott T. Tagawa, Paweł Zalewski, Florence Joly, Yohann Loriot, Gencay Hatiboglu, Luca Gianni, Franco Morelli ほか 127 名 - The Lancet Oncology 2020 被引用: 498

  11. Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Cancer 2022 被引用: 263

  12. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2022 被引用: 307

  13. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

    著者: , , , , , , , , , , , , , , , , , , , - ESMO Open 2020 被引用: 522

  14. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christian Kollmannsberger, Michael R. Harrison, Yoshihiko Tomita, Ignacio Durán, Viktor Grünwald, M. Brent McHenry, Sabeen Mekan, Nizar M. Tannir - The Lancet Oncology 2019 被引用: 780

  15. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

    著者: , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 被引用: 199

  16. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joseph E. Burgents, Rodolfo F. Perini, Thomas Powles - New England Journal of Medicine 2024 被引用: 285

  17. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 211

  18. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Piotr Sawrycki, Naomi B. Haas, Howard Gurney, Mauricio Mahave, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Christine Chevreau, John M. Burke, Gurjyot K. Doshi, Bohuslav Melichar, Delphine Topart, Stéphane Oudard, Evgeniy Kopyltsov, H. Hammers, David I. Quinn, Ajjai Alva, Juliana de Menezes, Adriano Gonçalves e Silva, Eric Winquist, Alketa Hamzaj, Giuseppe Procopio, Boguslawa Karaszewska, Ewa M. Nowakowska-Zajdel, B. Yа. Alekseev, Rustem Gafanov, А. А. Измайлов, Andrey Semenov, S. G. Afanasyev, Oleg Lipatov, T.B. Powles, Sandy Srinivas, David F. McDermott, Samith T. Kochuparambil, Ian D. Davis, Katriina Peltola, Roberto Sabbatini, Jinsoo Chung, М. I. Shkolnik, В. Б. Матвеев, P. Gajate Borau, Steven McCune, Thomas E. Hutson, Alejandro Dri, Silvio Correia Sales, Carrie Yeung, Carmen Marcela Alcala Castro, Peter J. Boström, Brigitte Laguerre, Consuelo Buttigliero, Ugo De Giorgi, Eugeniy A. Fomin, Yousef Zakharia, Clara Hwang, Eric A. Singer, Jeffrey T. Yorio, David Waterhouse, Rubén Dario Kowalyszyn, Margarita Sonia Alfie, Eduardo Yañez Ruiz, Tomáš Büchler, Krista Kankaanranta, G. Ferretti, Go Kimura, Kazuo Nishimura, Naoya Masumori, Satoshi Tamada, Haruaki Kato, Hiroshi Kitamura, Iwona Danielewicz ほか 133 名 - The Lancet Oncology 2022 被引用: 278

  19. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2020 被引用: 461

  20. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nizar M. Tannir - Cancer 2020 被引用: 337

  21. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2019 被引用: 488

  22. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter Schatteman, Nicolaas Lumen, Luc Dirix, Jean-Charles Goeminne, Thierry Gil, Emmanuel Seront, Christof Vulsteke, Celio Kussumoto, Fabio A. Franke, Fabricio Augusto Martinelli de Oliveira, Andrea Juliana Pereira de Santana Gomes, Hélio Pinczowski, Daniel D'Almeida Preto, Luis Eduardo Zucca, Giuliano Santos Borges, Andre M. Murad, Fred Saad, Kim N. Chi, Yves Fradet, Neil E. Fleshner, Urban Emmenegger, Klaus Brasso, Karim Fizazi, Stephane Culine, Antoine Thiery-Vuillemin, Florence Joly, Aude Fléchon, Werner Hilgers, Jean-Christophe Eymard, Delphine Borchiellini, Philippe Barthélémy, Raanan Berger, Raya Leibowitz-Amit, Wilmosh Mermershtain, Keren Rouvinov, Avivit Peer, Svetlana Kovel, Avishay Sella, Martijn P. Lolkema, Alfonsus J.M. van den Eertwegh, Johannes Voortman, Maureen J. Aarts, Jourik A. Gietema, Choung-Soo Kim, Young-Deuk Choi, Byung-Ha Chung, Rustem A. Gafanov, Evgeniy Kopyltsov, Evgeny A. Usynin, Joan Carles, Begoña Mellado, José Pablo Maroto, Jesús García-Donás, Juan Francisco Rodríguez Moreno, Ignacio Durán, Begoña Pérez-Valderrama, Elena Castro, David Olmos, María José Méndez-Vidal, David Lorente Estellés, Regina Gironés Sarrió, José Muñoz-Langa, Urbano Anido Herranz, Javier Puente Vázquez, Enrique Castellanos, Martin Hellström, Anders Widmark, Ingela Franck Lissbrant, Åsa Jellvert, Cecilia Külich ほか 34 名 - The Lancet Oncology 2022 被引用: 186

  23. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Karla Rodriguez-Lopez, Joseph E. Burgents, Cixin He, Chinyere E. Okpara, Jodi A. McKenzie, Toni K. Choueiri, for the CLEAR Trial Investigators, Robert J. Motzer, Toni K. Choueiri, Thomas E. Hutson, Luke T. Nordquist, David R. Spigel, Jaime R. Merchan, Saby George, Sandhya Srinivas, Brendan D. Curti, Andrew Pippas, Elisabeth I. Heath, Subramanya Rao, Theodore Stewart Gourdin, Mehmood Hashmi, Nafisa Burhani, Ana M. Molina, Alan J. Koletsky, Robert Alter, C. Alemany, Benjamin A. Gartrell, Mike Cusnir, Harsha Vyas, Stephanie L. Graff, Christian Squillante, Mark Knapp, Ivor Percent, Vijay Patel, Daniel L. Spitz, C. Harkness, Marc Matrana, Lindsay Overton, Stephen Richey, Donald Richards, Habib M. Ghaddar, Robert Galamaga, Ralph J. Hauke, Joseph Haggerty, Ronald Harris, Mark Johns, Samith T. Kochuparambil, Christian Kollmannsberger, Bobby Shayegan, Christina Canil, Eric Winquist, Catherine Sperlich, Georg A. Bjarnason, Naveen S. Basappa, Wolfgang Loidl, Wolfgang Horninger, Manuela Schmidinger, Lionel D’Hondt, Dirk Schrijvers, Annemie Rutten, Peter Schatteman, Wim Wynendaele, Daisy Luyten, Spyridon Sideris, Christine Gennigens, Bohuslav Melichar, Jana Katolická, Jiří Tomášek, Jana Prausová, Tomáš Büchler ほか 141 名 - Journal of Clinical Oncology 2024 被引用: 158

  24. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 被引用: 149